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Abstract Antimicrobial resistance (AMR) is a global public health threat. Emergence of AMR occurs naturally, but can also
be selected for by antimicrobial exposure in clinical and veterinary medicine. Despite growing worldwide attention to AMR,
there are substantial limitations in our understanding of the burden, distribution and determinants of AMR at the population
level. We highlight the importance of population-based approaches to assess the association between antimicrobial use and
AMR in humans and animals. Such approaches are needed to improve our understanding of the development and spread of
AMR in order to inform strategies for the prevention, detection and management of AMR, and to support the sustainable
use of antimicrobials in healthcare.
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Introduction
Antimicrobial resistance (AMR) – the ability of microbes to
grow in the presence of a drug that would normally kill them
or limit their growth [1] – is a major global public health
concern [2, 3]. AMR complicates the treatment of infection
and is associated with increased morbidity and mortality.
The emergence and spread of resistant and multidrug-
resistant (MDR) bacteria has enormous implications for
worldwide healthcare delivery and population health
[4, 5]. The reporting of bacterial isolates that have transmis-
sible resistance to carbapenems and colistin (considered to
be the last-line antibiotics for MDR Gram-negative bacterial
infections) emphasises this major public health threat [6].
Furthermore, the lack of development of new antimicrobials
in over two decades adds to the urgency of preserving the
antimicrobial efficacy of currently available drugs. Although
the role of antimicrobial use in the development of AMR
has been studied extensively, the emergence, distribution
and transmission of AMR in populations is complex and
poorly understood. AMR in populations is influenced by bac-
terial, host, and environmental factors, including exposure to
antimicrobials in clinical medicine, environmental waste and
contamination, food production and animal husbandry [7–
9]. Here, we review the current understanding of mechan-
isms underlying AMR at the population and individual level,
specifically highlighting gaps where further research is needed
across all income settings. Understanding the determinants of
AMR in the community will be fundamental in developing
effective strategies to prevent and manage AMR.
The burden of AMR
Antimicrobials have played a crucial role in reducing mor-
bidity and mortality from infectious diseases. However,
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these healthcare gains are now under threat because of the
emergence and spread of organisms that are resistant to
antimicrobials [4, 5]. In recent decades, AMR has become
a widespread problem in all countries, irrespective of their
level of income. In 2014, a synthesis of evidence and economic
review indicated that an estimated 700,000 deaths globally
were attributable to infections caused by antibiotic-resistant
organisms, and this is expected to reach 10 million/year by
2050 [4, 10, 11]. It has also been predicted that the mortality
from infections inwhichAMR is a factor could result in a reduc-
tion of 2% to 3.5% in global gross domestic product in 2050,
amounting to between 60 and 100 trillion US dollars, globally
[4, 10, 11]. This economic cost may be more evident in low-
and middle-income countries (LMICs); however, the impact
of AMR on these LMICs remains largely unknown [12]. The
costs associated with AMR are likely to increase as resistance
to second- and third-generation antibiotics develops, leading
to scenarios where critically ill patients need supportive care,
and antibiotics no longer have therapeutic efficacy [13].
Mechanisms of AMR
The development of AMR is primarily due to selective pres-
sure on microorganisms – as a result of exposure to antimi-
crobials. There are several mechanisms by which organisms
can adapt and become resistant to antimicrobials; these
include the production of enzymes, alteration of target
sites, alteration of metabolic pathways, alteration of outer
membrane permeability and efflux pumps [14]. Resistant
bacteria may possess one or more of these mechanisms,
and thus exhibit resistance to more than one class of anti-
microbial. Genetic variation is essential for microbial evolu-
tion, and may arise by a variety of mechanisms including
point mutations, rearrangements of large segments of
DNA from one location of a chromosome or plasmid to
another, or acquisition of foreign DNA from other bacteria
by horizontal transfer of mobile genetic elements. A single
mutation that confers AMR in a bacterium in a population
under selection pressure can enable survival of that organ-
ism where all other susceptible organisms are killed [15].
The resistant organisms can continue to replicate, becoming
the dominant variant [15].
AMR surveillance
The first step to tackling AMR is to determine the burden
and understand its determinants before implementing public
health policies to contain it. Whilst the USA and many
European countries have surveillance systems in place, these
are mostly lacking in low-resource settings. Surveillance of
AMR in these regions is limited by the lack of laboratory infra-
structure for monitoring infections and detecting resistance.
Smaller studies examining the prevalence of AMR in these
regions are likely to be hospital-based, and potentially over-
estimate the prevalence of AMR [2]. Development of national
and regional collaborative surveillance networks with free data
sharing may provide important frameworks for successful
monitoring and reporting in these regions. Dissemination of
trend information from such setups and engagement with
policy-makers would be essential to devising regional strategies
for containment ofAMR.One example of such a network is the
ReLAVRA (the Latin American Antimicrobial Resistance
Surveillance Network) created in 1996 by the World Health
Organization regional office to collect and aggregate data
from National Reference Laboratories in the region [2]. This
has greatly improved the ability to detect and monitor AMR,
and has played a role in guiding policy towards antimicrobial
use in this region. Transposing similar efforts to surveillance
of AMR in other settings such as Africa and South-East Asia
will be essential to developing a global response to AMR.
Antimicrobial use and AMR in humans and other
animals
The use of antimicrobials in clinical medicine has materially
decreased the burden of infectious diseases and facilitated
complex medical interventions such as organ transplantation
and advanced surgery [5]. Antimicrobial use, misuse or
overuse in clinical medicine is a major contributing factor
in the development of AMR in human populations [3, 16–
18]. Antimicrobials are also widely used in domestic animals
and livestock [19]. Sub-therapeutic doses of antimicrobials
are used for growth-promotion in some countries [20].
Although the use of antimicrobials as growth promoters
has been discontinued in the European Union since 2006
[21], this practice continues in the Americas and Asia
[22]. Current livestock husbandry systems lead to relatively
high levels of endemic disease [19] but, in the case of pigs
and poultry, it is often uneconomic to provide treatment
at the individual animal level, leading to the blanket treat-
ment of groups of animals, normally delivered via the feed
or water [23]. Together with antimicrobial exposure in
the environment, antimicrobial use in humans and other ani-
mals is thought to be an important selective pressure for
AMR globally [19, 24]. Additionally, there are important
gaps in our understanding of the role of food-borne bacteria,
and their impact on health at the population level [2].
Implementing surveillance of AMR relating to food products
would require integrated surveillance of AMR at hospital and
community levels, including surveillance of AMR in food-
producing animals [2]. Data surveillance networks at the
national and global levels that could potentially identify and
collect information promptly on index cases are necessary
to better understand the impact of these factors.
Transmission of AMR among human and animal
populations
There is an intricate interplay between humans, animals and
the environment in relation to the development and spread
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of AMR [7, 8, 25]. There have been many studies exploring
the association between antimicrobial use in animals and
resistance in humans, involving direct and indirect routes
of transmission [19]. In 2015, the European Centre for
Disease Prevention and Control, the European Food
Safety Authority and the European Medicines Agency con-
ducted an aggregated analysis of surveillance data from
across the EU, assessing the relationship between human
and animal use of antibiotics and AMR [26]. They reported
that studies showed positive associations between consump-
tion of antimicrobials and resistance in bacteria in both
humans and animals. Some studies also found positive asso-
ciations between antimicrobial consumption in animals and
resistance in bacteria from humans. However, the aggre-
gated European data also show varied or inconsistent asso-
ciations among specific pathogens and AMR in humans and
animals [26]. Whilst there are some studies that have
shown that farm animals do not share common populations
of some bacterial strains with humans [27], the emergence
of livestock-associated methicillin-resistant Staphylococcus
aureus (MRSA) such as clonal complex 398 (CC 398) [28]
and mecC MRSA in a wide range of host species [29, 30]
has shown that these antimicrobial-resistant lineages
represent a common population shared by humans and
farm animals. These assessments recapitulate the need to
interpret such data with caution. By their nature, these
aggregated data analyses of observational evidence are
also limited by potential confounding factors [31, 32] – high-
lighting the need for more detailed and context-specific
studies to examine the associations among antimicrobial
exposure in humans and other animals, and the develop-
ment of AMR.
The integration of genetic and epidemiological approaches,
including targeted and whole-genome sequencing methods,
has allowed the examination of the evolutionary origins
of pathogens in both human and other animal populations.
Analyses of sequence data suggest that a globally distributed
MRSA lineage (ST5) may have originated after human-
to-poultry transmission [33]. Conversely, studies have also
shown that various MRSA lineages from animals also appear
in humans [34, 35]. However, the direction of transmission
(human-to-animal or animal-to-human) may be equivocal.
Although there is evidence to indicate that third-generation
cephalosporin-resistant Escherichia coli strains can spread
from livestock to humans via food consumption [36, 37],
a recent study suggested that such cephalosporin resistance
genes are mainly disseminated in animals and humans
via distinct plasmids [38]. Similarly, whole-genome
sequencing analyses suggest that the multidrug-resistant
Salmonella Typhimurium DT104 bacterium and its resistance
genes are distinct between animal and human populations
with limited transmission between the two [39].
Collectively, these studies highlight the complexities in
understanding the burden and transmission of AMR among
populations.
The need for epidemiological surveillance using
sequencing technologies
Despite growing worldwide attention, there are substantial
limitations in our understanding of the burden, distribution
and determinants of AMR at the population level. A recent
systematic review of studies assessing the observational evi-
dence for an association between antimicrobial use and devel-
opment of MRSA resistance found that individual study
reporting was poor [40]. This highlights the broader need for
high-quality epidemiological evidence, including for populations
at high risk as well as those that are globally representative.
Population prevalence studies are important for understanding
the burden ofAMR in a given setting and for informing context-
specific treatment practices [41]. Such studies, in parallel to
those assessing the health impact of antimicrobial-resistant
pathogens, would help to inform the development of preventa-
tive interventions. Importantly, augmenting existing surveil-
lance programmes will be central to this objective.
With a lack of new therapeutic agents to target resistant
bacterial infections, it is increasingly important to under-
stand the factors that contribute to the emergence of
AMR. While most preventative strategies emphasise the
need to reduce antimicrobial misuse and overuse by health
providers, the lack of advice regarding specific interventions
that are likely to have an impact on reduction in AMR in the
hospital and community setting limits the implementation of
such guidance. Well-designed large-scale epidemiological
studies are needed to understand the relationship between
AMR and distinct patterns of antimicrobial prescribing and
consumption, in order to inform specific guidelines for
AMR stewardship in humans as well as agricultural treat-
ment practices. Such research could also facilitate identifica-
tion of high-risk populations (human and animal) for AMR
transmission, and provide specific guidance for prevention
and treatment in these subgroups. There is a need to assess
this association in both hospital and community settings,
including the use of routine clinical data, electronic health
records (EHRs) and concomitant pathogen surveillance, as
well as capitalising on experimental/interventional designs
[42]. Potentially comparable data exist, but are limited
because of a lack of standardised approaches for measuring
resistance and harmonised surveillance and data collection
guidelines. More data are needed to understand the complex
relationship between antimicrobial use and consumption in
many different settings, and the prevalence of AMR in
humans and other animals. Integrated surveillance of AMR
in food-producing animals, foods, and humans globally with
standardised approaches and timely sharing of data is key
to identifying potential routes and sources of transmission
[2]. Sequencing-based approaches will play an important
role in this endeavour [43]. These integrated approaches
in human and animal populations will provide opportunities
to help determine the evolutionary origins of pathogen
lineages in both human and animal populations.
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In addition to limitations of population-based epidemio-
logical studies of AMR, there is also a gap in individual-level
data to assess individual patient outcomes in response to
antimicrobial use [7]. Existing systems, such as EHRs,
could be utilised to help facilitate such studies, including
the recruitment of individuals at the time of diagnosis of spe-
cific clinical indications, as well as documenting antibiotic
treatment. EHRs could provide information on prescribing
practices and the incidence of drug-resistant and MDR infec-
tions in hospital and community settings. Such an approach
could provide strategies to assess the impact of empirical
antimicrobial use in human populations and the prevalence
of AMR. This may also enable a better understanding of
the predictors of AMR, helping to identify and target emer-
ging resistant infections. A critical element of such research
will be to consider prospective designs (longitudinal studies),
particularly in specific contexts – defined by geographical
regions, communities and dominant pathways of potential
zoonotic transmission. Such prospective designs would
allow the real-time study of the development of resistant
strains in the population, and allow a detailed examination
of factors that encourage and impede the spread of AMR
[42]. However, E-health systems have their limitations,
including disparities in reporting and inconsistencies in com-
pleteness and reliability. Furthermore, whilst E-health sys-
tems have been established in a number of high-income
settings, this is still a nascent field in LMICs. The utility of
EHRs for epidemiological research into AMR first requires
the implementation of E-health systems in LMICs, which
will need to involve improved technical infrastructure and
connectivity, technical capacity building and solutions to
ensure sustainability and use of such systems. Where sur-
veillance and clinical databases exist, these potentially pro-
vide a framework for epidemiological studies of AMR.
However, these programmes will need to be expanded to
include reporting of animal infections and AMR, as well as
veterinary prescribing practices. Furthermore, sharing and
accumulation of these data through a central repository
could enable an assessment of this relationship on a national
or regional scale.
Prevention and treatment
As well as efforts to increase our understanding of the fac-
tors contributing to the emergence and spread of AMR,
there are preventative strategies that could help to reduce
its burden. Preventing the spread of infections in the first
instance would reduce the need to use antimicrobials and,
consequently, might moderate the development of resistant
infections. There are a number of ways in which this might
be achieved. Examples include immunisation, safe food prep-
aration, infection control measures (e.g. hand hygiene, bar-
rier precautions and isolation of infected patients) and
improved waste management to prevent the spread of
resistant organisms in the hospital, community, agricultural
and environmental settings. However, basic health interven-
tions, such as good hygiene practices and adherence to anti-
microbial stewardship, can be particularly difficult to achieve
in some LMICs [44]. Furthermore, human resource con-
straints and weak health infrastructures limit the surveillance
and management of AMR [45, 46]. It will therefore be
important to tailor AMR preventative measures to the
local context in order to make them achievable and effect-
ive. The development of rapid diagnostic tests that could
be used in both low- and high-resource settings to rapidly
diagnose bacterial infection and identify markers of drug
resistance would also be beneficial to this endeavour.
Patterns of antimicrobial consumption are influenced by
multiple factors including self-diagnosis and treatment with
over-the-counter medications and local prescribing prac-
tices. The lack of point-of-care (POC) tests that are able
to reliably distinguish bacterial from viral infections means
that patients are frequently prescribed empirical antimicro-
bials whilst waiting for the results of microbiological tests
[47]. The dose or duration of treatment may also be sub-
optimal, allowing the emergence of resistant strains. A lack
of public understanding of AMR also influences patterns of
consumption. Patients often discontinue antimicrobial treat-
ment before the end of the treatment course, which sup-
ports the selection of antimicrobial resistant organisms [3].
Only half of countries have implemented a campaign for
public education on the use of antimicrobials, and the major-
ity of these countries are higher-income [48]. Furthermore,
the availability and use of substandard or counterfeit antimi-
crobials adds to the challenges of antimicrobial stewardship,
as well as risking lives [49, 50].
Increasing globalisation also contributes to the develop-
ment and spread of AMR. Population movement facilitates
the spread of resistant infections from areas of high to
low prevalence. However, the risk of imported
drug-resistant infections is difficult to quantify and better
international surveillance is needed to detect and monitor
these infections. Deployment of new technologies, such as
next-generation sequencing, could help to better under-
stand the origin of organisms, and the role of population
movement in the spread of AMR. Furthermore, in LMICs
that are undergoing rapid economic development, urbanisa-
tion has resulted in overcrowding and poor sanitation.
Development may also result in a rise in migration from
rural to urban areas. This not only increases exposure of
susceptible populations to drug-resistant infections, but fur-
ther contributes to the problem of overcrowding.
Collectively, these factors associated with urbanisation
increase the risk of the development and spread of AMR.
Better control of the spread of AMR will rely on a multi-
sectorial approach and the involvement of stakeholders on
a global scale.
Antimicrobial stewardship programmes (ASPs) involve a
number of interventions to promote prudent antimicrobial
use and reduce AMR, through evidence-based treatment
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regimens. EHR systems have recently been shown to pro-
vide a successful framework for ASPs [51]. These pro-
grammes require indications and criteria for specific
antibiotic use to be specified prior to use. They also prompt
clinicians to rationalise or discontinue antibiotic therapy
after 48–72 h, in response to microbiology results.
Additionally, by the creation of order sets, software develo-
pers can direct antibiotic prescribing towards a preferred
regimen, when one regimen is noted to be associated with
higher AMR, based on EHR surveillance [51]. Such interven-
tion depends on the availability of comprehensive ecological
and epidemiological data on AMR locally, nationally and even
globally. One barrier to widespread implementation of ASPs
is the financial cost of training, particularly in LMICs [46].
However, ASPs have been shown to be cost-effective and
to reduce costs in the long term [46]. ASPs should be imple-
mented alongside other effective interventions such as hand
hygiene, which has been shown to reduce antimicrobial
resistant infections [52]. Furthermore, across all income set-
tings it will be important to promote integration with other
programmes for pharmacy management, microbiology, POC
diagnostics and laboratory quality control [46].
The advancement of precision medicine will provide add-
itional opportunities to reduce the emergence and spread of
AMR. On the one hand, it will enable the delivery of more
targeted therapy against the infective organism. On the
other hand, it may help to predict to susceptibility to infec-
tion, severity of disease or response to treatment in the
infected individual. The application of a precision medicine
approach may also help to reduce unnecessary antimicrobial
prescribing and thus slow the emergence and spread of
resistance. However, this approach often requires the avail-
ability of accurate, rapid and affordable diagnostic tests if we
are to derive the potential health care benefits.
Finally, there is an urgent need to develop new thera-
peutic options for treating drug-resistant infections. Since
1987, no new class of antibiotics has been discovered and
drug development has largely relied on structural changes
to existing compounds [53, 54]. Challenges in target selec-
tion, especially targets that are essential, conserved and
not susceptible to the rapid development of resistance,
limit the success of antibiotic drug discovery and develop-
ment. Further, the low risk of success and the high
economic costs associated with drug development have
become a major disincentive for pharmaceutical companies
and resulted in many of them withdrawing from this field.
Academic institutions are unable to take new antimicrobials
beyond early stage development without industrial partners.
Any new antimicrobials that are developed for the treat-
ment of resistant and MDR infections will need to be highly
restricted in their use, further reducing incentive for com-
mercial drug development. A paradigm shift towards a
new model for drug development that brings together aca-
demia, pharmaceutical companies and governments to
share the risks and costs of drug development for public
benefit is required. This solution has been proposed by
the O’Neill Review on AMR [55].
Conclusion
AMR is a global public health threat. Despite growing world-
wide attention to AMR, there are substantial limitations in
our understanding of the burden, distribution and determi-
nants of AMR at the population level. The integration of a
broad range of context-specific epidemiological study
designs is needed to improve our understanding of the bur-
den of AMR in populations, as well as the population-level
factors influencing the development and spread of AMR
[32]. Together with stewardship initiatives, such studies
will better inform strategies for the detection, prevention
and management of AMR and to support the continued
use of antimicrobials in healthcare.
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